Nautilus Biotechnology Inc. (NAUT)
NASDAQ: NAUTHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 1.94 -0.92%
NAUT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $249.42M
- EPS (TTM)
- -$0.50
- Dividend yield
- None
- 52-week range
- 0.82 – 4.31
- Day range
- 1.62 – 2.17
- Volume / Avg
- 12.47M / 2.43M
- Beta
- —
- Shares outstanding
- 127.26M
- Next earnings
- Oct 26, 2026
52-week range
NAUT stock today
On Oct 7, NAUT ended the session at $1.96, adding $0.19 (10.73%), versus the S&P 500's 0.22% decline. Volume was 5.1x the average at 12.47M shares, a sign of unusually heavy trading. At this level, NAUT sits in the middle of its 52-week range of $0.82 to $4.31: 54.5% below the high, set on Mar 25, 2026 and 139.0% above the low.
NAUT is up 0.5% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 126.3%. Nautilus Biotechnology has posted a net loss over the last twelve months (EPS of -$0.50), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 26; analysts expect EPS of -$0.14.
Summary generated from market data by MetaCap's automated system. Methodology
About Nautilus Biotechnology
Company profileNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Sujal M. Patel
- Headquarters
- Seattle, WA
- Employees
- 127
- IPO year
- 2020
- Website
- nautilus.bio
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$3.83+95.41%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 26, 2026
- EPS estimate
- $-0.14
Nautilus Biotechnology peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMRXImmuneering Corporation Class A | 3.86 | +0.78% | $249.73M | vs NAUT |
| ZNTLZentalis Pharmaceuticals Inc. | 2.55 | -4.49% | $250.21M | vs NAUT |
| UPBUpstream Bio Inc. | 4.61 | +0.44% | $252.49M | vs NAUT |
| ACIUAC Immune SA | 2.57 | +1.98% | $255.53M | vs NAUT |
| STROSutro Biopharma Inc. | 14.66 | +1.45% | $243.08M | vs NAUT |
| FATEFate Therapeutics Inc. | 2.15 | -6.11% | $257.61M | vs NAUT |
| CAMPCAMP4 Therapeutics Corporation | 3.84 | -3.03% | $240.97M | vs NAUT |
| PALIPalisade Bio Inc. | 1.48 | -0.67% | $257.92M | vs NAUT |
Indexes, lists and sector
Appears in lists
Nautilus Biotechnology stock FAQ
What is Nautilus Biotechnology's stock price today?
NAUT last traded at $1.96 as of Oct 7, 4:00 PM EDT, up 10.73% on the day. Prices are delayed at least 15 minutes.
When is Nautilus Biotechnology's next earnings date?
Nautilus Biotechnology is expected to report earnings on Monday, October 26, 2026. Analysts expect EPS of $-0.14.
Who is Nautilus Biotechnology's CEO?
Mr. Sujal M. Patel is the chief executive officer of Nautilus Biotechnology Inc., which has about 127 employees.
What is the NAUT 52-week high?
The 52-week high for NAUT is $4.31 and the 52-week low is $0.82. The stock is currently 54.5% below its high.